Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GB:0QYQ)
LSE:0QYQ
Gilead Sciences (0QYQ) Share Price & Analysis
1 Followers
0QYQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.14 - $87.53
Previous Close$76.01
Volume20.52K
Average Volume (3M)34.50K
Market Cap
$95.32B
Enterprise Value$120.43B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$25.19B
Price to Earnings (P/E)211.9
Beta0.61
Next Earnings
Aug 08, 2024EPS Estimate
$1.6Last Dividend Ex-Date
Jun 14, 2024Dividend Yield4.14%
Share Statistics
EPS (TTM)0.36
Shares Outstanding1,245,853,209
10 Day Avg. Volume14,408
30 Day Avg. Volume34,504
Standard Deviation0.07
R-Squared0.00951
Alpha-0.00337
Financial Highlights & Ratios
Price to Book (P/B)-7.38
Price to Sales (P/S)11.52
Price to Cash Flow (P/CF)10.20
P/FCF Ratio10.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.39
Enterprise Value/Gross Profit5.84
Enterprise Value/Ebitda25.17
Forecast
1Y Price Target
$81.26Price Target Upside6.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Gilead Sciences News
Bulls Say, Bears Say
Bulls Say
HIV PreventionRecent outstanding data from PURPOSE-1 study of long acting lenacapavir in HIV pre-exposure prophylaxis (PrEP) and expected approval of seladelpar in PBC are likely to outpace current expectations.
Market GrowthCollectively, lenacapavir PrEP and seladelpar could contribute multi-billion dollar top-line growth over the next five years.
Obesity TreatmentGS-4571 shows promising weight loss results in non-human primates and mice, indicating potential efficacy.
Bears Say
Drug DevelopmentGilead hasn't said 'if or when GS-4571 will enter Phase 1,' raising concerns about the asset’s future development.
Market PerformanceGILD has been a laggard with a -21% year-to-date performance compared to its peers, and sentiment remains lackluster on the pipeline.
OncologyTrodelvy's failed to demonstrate a statistically significant improvement in overall survival compared to chemotherapy, missing the study’s primary endpoint.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.91% Insiders
30.71% Mutual Funds
29.34% Other Institutional Investors
39.05% Public Companies and
Individual Investors
0QYQ FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest share price was $62.14 and its highest was $87.53 in the past 12 months.
What is Gilead Sciences’s market cap?
Currently, no data Available
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Aug 08, 2024 which is in 12 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Apr 25, 2024. The company reported -$1.32 earnings per share for the quarter, beating the consensus estimate of -$1.493 by $0.173.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 4.14%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is $1.6.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,245,853,100 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of -$1.32 in its last earnings report, beating expectations of -$1.493. Following the earnings report the stock price went up 0.142%.
Which hedge fund is a major shareholder of Gilead Sciences?
Among the largest hedge funds holding Gilead Sciences’s share is Dodge & Cox. It holds Gilead Sciences’s shares valued at 2B.
---
Gilead Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$81.26 (6.91% Upside)
$81.26 (6.91% Upside)
Blogger Sentiment
Bullish
GB:0QYQ Sentiment 94%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.23%
12-Months-Change
Fundamentals
Return on Equity
2.51%
Trailing 12-Months
Asset Growth
-9.02%
Trailing 12-Months
Company Description
Gilead Sciences
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
---
0QYQ Company Deck
---
0QYQ Earnings Call
Q1 2024
0:00 / 0:00
---
0QYQ Revenue Breakdown
67.03% HIV
8.05% Veklury
6.89% Cell Therapy
6.52% HCV
11.51% Other
---
0QYQ Stock 12 Month Forecast
Average Price Target
$81.26
▲(6.91% Upside)
Technical Analysis
Best Analysts Covering 0QYQ
1 Year
1 Year Success Rate
35/60 ratings generated profit
1 Year Average Return
+6.68%
assigned a buy rating last month
Copying Salim Syed's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +6.68% per trade.
---